|
|
Article: YORK PHARMA PLC - Research Update - Phase II trial of YP003.
- Article from:
- PR Newswire UK Disclose
- Article date:
- June 30, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
York Pharma starts Phase II Clinical Development of YP003 in Psoriasis
Hitchin, UK, 30 June 2005 York Pharma plc, the AIM-listed (AIM:YRK) strategic
acquirer, developer and marketer of pharmaceutical products in the field of
dermatology, announces ethics committee approval for the start of a Phase II
study in Australia of YP003, the company's patented product with potential in
the treatment of psoriasis. Dosing of patients will commence shortly, and the
study is expected to complete by the end of 2005. The psoriasis market is
valued at approximately $630m currently and projected to grow to $2bn by 20081.
The randomised, double-blind Phase II study will compare the ...